Duchenne muscular dystrophy (DMD) is a fatal X-linked muscle wasting disease caused by mutations of the gene encoding the cytoskeletal protein dystrophin. Therapeutic options for DMD are limited because the pathogenetic mechanism by which dystrophin deficiency produces the clinical phenotype remains obscure. Recent reports of abnormal α-adrenergic vasoregulation in exercising muscles of DMD patients and in the mdx mouse, an animal model of DMD, prompted us to hypothesize that the dystrophin-deficient smooth muscle contributes to the vascular and dystrophic phenotypes of DMD. To test this, we generated transgenic mdx mice which express dystrophin only in smooth muscle (SMTg/mdx). We found that α-adrenergic vasoconstriction was markedly attenuated in the contracting hindlimbs of C57BL/10 wild type mice, an effect that was mediated by nitric oxide (NO) and was severely impaired in the mdx mice. SMTg/mdx mice showed an intermediate phenotype, with partial restoration of the NO-dependent modulation of α-adrenergic vasoconstriction in active muscle. In addition, the elevated serum creatine kinase levels observed in mdx mice were significantly reduced in SMTg/mdx mice. This is the first report of a functional role of dystrophin in vascular smooth muscle.
INTRODUCTION
Duchenne muscular dystrophy (DMD) is a severe muscle-wasting disease caused by mutations in the dystrophin gene that result in the absence of dystrophin in the sarcolemma of muscle fibers (1) . DMD is the most common muscular dystrophy, an X-linked recessive disorder that affects 1 in 3500 live males at birth (2) . A milder form of DMD known as Becker muscular dystrophy (BMD) also is caused by mutations in the dystrophin gene, resulting in low level expression of a truncated protein (3, 4) . Currently, there is no effective therapy for the dystrophinopathies because the mechanism by which dystrophin deficiency produces the clinical phenotype of progressive muscle weakness and respiratory and cardiac failure is poorly understood.
Dystrophin is localized to the sarcolemma in association with a highly organized complex of transmembrane and cytosolic proteins that forms a structural link between the extracellular matrix and the intracellular actin cytoskeleton (1, (5) (6) (7) . The loss of dystrophin destabilizes this complex, which is thought to increase the susceptibility of muscle cells to contraction-induced damage (8) .
Despite a uniform genetic defect, the characteristic histological phenotype observed in dystrophindeficient muscle is one of small, random groups of necrotic muscle cells surrounded by normal cells (9, 10) . We and others have shown that a similar pattern of focal necrosis can be induced by artificial infarction in healthy muscle, suggesting that vascular insufficiency may contribute to the dystrophic pathology (11) (12) (13) . We also have previously observed strong nerve growth factor 4 receptor (NGFR) immunoreactivity on the tunica adventitia of blood vessels in muscle specimens from DMD patients, but not in controls (14) . This suggests an aberration of the neurovascular system and/or blood vessels in DMD, because NGFR plays essential roles in the survival and maintenance of sympathetic and sensory neurons (15).
In fact, recent reports have indicated that sympathetic neurovascular control is abnormal in dystrophin-deficient muscle (16) (17) (18) . This defective regulation is observed during exercise, when sympathetic vasoconstriction normally is blunted in the active muscles by locally produced dilator substances, including nitric oxide (NO) (16, 17, (19) (20) (21) . In the exercising muscles of DMD patients and mdx mice, a naturally occuring animal model of DMD (22), constrictor responses to activation of either sympathetic nerves or vascular α-adrenergic receptors were abnormally preserved (16) (17) (18) .
This was attributed to a deficiency of neuronal nitric oxide synthase (nNOS), which normally associates with the dystrophin complex at the sarcolemma but is secondarily reduced in the absence of dystrophin (23, 24) . Based on these studies, dystrophin-deficiency in skeletal muscle was identified as the principal cause of the impairments in NO signaling and vasoregulation.
However, another possibility is that the impaired vasoregulation is due to dystrophindeficiency in vascular smooth muscle cells (VSMCs). Dystrophin is normally expressed in the tunica media of blood vessels, especially in the muscular arteries, but it is absent in vessels from mdx mice (25, 26). We now report that selective smooth muscle expression of full-length human 5 dystrophin, which is easily distinguished from endogenous mouse dystrophin, partially restores the NO-dependent attenuation of α-adrenergic vasoconstriction in exercising muscles of mdx mice.
Moreover these transgenic mdx mice have significantly reduced serum creatine kinase (CK) levels compared with those of the nontransgenic mdx mice. These data suggest that dystrophin in VSMCs may play an important role in the local autocrine regulation of α-adrenergic constriction, and that the loss of this regulatory mechanism may exacerbate muscle fiber necrosis. We have previously reported that dystrophin expression can be easily detected in VSMCs of lung in normal control mice by immunofluorescent staining whereas it is lacking in mdx mice (25). Therefore, to confirm dystrophin expression, we performed immunofluorescence labeling of tissue samples of skeletal muscle and lung (Fig. 1 ) using a polyclonal sheep anti-dystrophin antibody (60kDa; kindly provided by Dr. E.P. Hoffman) and a monoclonal mouse anti-dystrophin antibody (DYS2). As expected, dystrophin expression was detected in the skeletal muscle sarcolemma and in VSMCs of skeletal muscle and lung in C57BL/10 mice, but not in mdx mice. In the 3 lines of SMTg/mdx mice, dystrophin expression was detected only in VSMCs of skeletal muscle and lung ( Fig. 1B-J) . We also analyzed the expression of other components of the dystrophin-glycoprotein complex in smooth muscle using immunofluorescent staining for β-sarcoglycan and β-dystroglycan, and found no differences among the C57BL/10, SMTg/mdx and mdx mice (data not shown).
Immunoblotting analysis confirmed that dystrophin was expressed in skeletal muscle of C57BL/10 mice, but not of mdx or SMTg/mdx mice ( Fig. 2A) . Dystrophin also was expressed in aorta from C57BL/10 mice and from each of the SMTg/mdx lines, although the level of expression was lower than in C57BL/10 mice (Fig. 2B) . Similar results were obtained in the lung (data not shown). We estimated the expression pattern of the human dystrophin transgene in various tissues of one line of SMTg/mdx mice by semi-quantitative real-time RT-PCR using a probe and primers specific for human dystrophin. Expression of human dystrophin was high in the lung, aorta, small 8 intestine, and heart, but minimal in skeletal muscle (Fig. 2C) . This expression pattern coincides with the distribution of reporter genes under the control of the EA4.7 promoter (28). Taken together, these data indicate that the transgenic construct successfully expresses dystrophin in the VSMCs of SMTg/mdx mice with high specificity for smooth muscle, but that the dystrophin expression levels of SMTg/mdx lines were lower than those of C57BL/10 mice.
Selective expression of dystrophin in VSMCs partially normalizes α-adrenergic vasoregulation in the hindlimbs of the SMTg/mdx mice To evaluate the effect of dystrophin expression in VSMCs on vascular function in vivo, we assessed α-adrenergic vasoregulation in the hindlimbs of SMTg/mdx mice as previously described (16, 17) .
Compared to C57BL/10 mice, mean arterial blood pressures, femoral blood flow velocities (FBFV), and femoral vascular conductances (FVC) at rest and during contraction were similar in each group of mice, with the exception of higher resting FBFV and FVC in SMTg/mdx (23) and in mdx mice (Table 1) . Norepinephrine (NE) injected into the arterial supply of the resting hindlimbs caused prominent vasoconstriction in all of the mice, maximally decreasing FBFV by 31 to 46% and FVC by 38 to 47% (Fig. 3 and Fig. 4A ). The amount of NE injected to cause these vasoconstrictor responses did not differ among C57BL/10 (6.7±0.8 ng), SMTg/mdx (7.7±1.1, 8.6±0.9, and 8.1±0.5 ng for lines 10, 23, and 26, respectively), and mdx mice (7.1±0.6 ng). When injected into the 4A ). Similar results were obtained when the NE-mediated decreases in FBFV and FVC were expressed as integrated areas to reflect the total, rather than just the peak, vasoconstrictor responses ( Fig. 4B and C) . Collectively, these data indicate that dystrophin in VSMCs plays an important role in the coordinated vascular response to competing constrictor and dilator signals.
NOS Inhibition enhances α-adrenergic vasoconstriction in the contracting hindlimbs of

SMTg/mdx mice
Because NO deficiency has been implicated in the impaired vasoregulation observed in mdx mice in previous studies (16, 17) , we wanted to determine if dystrophin expression in VSMCs improved NO signaling in the SMTg/mdx mice. The NOS inhibitor N-nitro-L-arginine methyl ester (L-NAME) increased mean arterial pressure and decreased FBFV and FVC similarly in C57BL/10, SMTg/mdx, and mdx mice ( Table 2 ). L-NAME had no effect on NE-mediated vasoconstriction in the resting hindlimb ( Fig. 5A-B) . In contrast, L-NAME significantly enhanced the vasoconstrictor responses to NE in the contracting hindlimbs of the C57BL/10 mice, while it caused no further at Pennsylvania State University on February 21, 2013 http://hmg.oxfordjournals.org/ Downloaded from enhancement of these responses in the contracting hindlimbs of the mdx mice (Fig. 5A-C) .
Intriguingly, L-NAME also enhanced NE-mediated vasoconstriction in the contracting hindlimbs of the SMTg/mdx mice, although to a lesser extent than it did in the C57BL/10 mice ( Fig. 5A-C ).
Western blot analysis for nNOS, which is the predominant NOS isoform found in smooth muscle (29, 30) , showed similar expression in the aortas of C57BL/10 and SMTg/mdx mice, but reduced expression in the mdx mice (Fig. 5D ). These results suggest that dystrophin restoration in smooth muscle upregulates nNOS expression, which may contribute to the NO-dependent attenuation of NE-mediated vasoconstriction.
Restoration of dystrophin in VSMCs reduces serum CK levels in SMTg/mdx mice
To determine if dystrophin restoration in smooth muscle ameliorates the skeletal muscle phenotype, we evaluated serum CK levels and muscle histopathology in the SMTg/mdx mice (Fig. 6 ). CK levels of 1-year-old SMTg/mdx mice (1030±170, 766±207, and 1128±301 units in lines 10, 23, 26, respectively) were higher than those of C57BL/10 mice (151±43 units), but they were dramatically reduced compared with those of age-matched mdx mice (4145±861 units) (Fig. 6A) . However, the histopathology of SMTg/mdx mice was not improved (Fig. 6B-D) . The number of centrally nucleated muscle fibers in SMTg/mdx mice was not significantly different from that in mdx mice DISCUSSION This is the first study to evaluate the effect of selective dystrophin expression in smooth muscle on vascular regulation and skeletal muscle dystrophy in the mdx mouse. Previous studies have shown that the normally robust NO-dependent attenuation of α-adrenergic vasoconstriction that occurs in exercising muscle is impaired in the dystrophin-deficient mdx mouse (16, 17, 20) . We now report that this impairment is partially reversed in 3 independent lines of transgenic mdx mice that express dystrophin only in smooth muscle (SMTg/mdx mice). In addition, the characteristic elevation in serum creatine kinase that occurs in mdx mice was markedly attenuated in the SMTg/mdx mice. These findings suggest that expression of dystrophin in smooth muscle improved both the vascular and dystrophic phenotypes of the mdx mouse.
Our study provides new insight into the function of dystrophin in blood vessels, particularly in the resistance vessels of the skeletal muscle circulation. We found that there were no consistent or striking differences in basal blood pressures or hindlimb blood flows among the wild type, SMTg/mdx, and mdx mice under anesthesia. Also, peak vasoconstrictor responses to intra-arterial injections of NE into the resting hindlimbs were similar among the 3 genotypes. Taken together, these data suggest that dystrophin in VSMCs is not essential to maintain normal vascular tone or to evoke acute increases in tone in the skeletal muscle circulation. In agreement with these in vivo results, a previous in vitro study of smooth muscle from wild type and mdx mice showed that In contrast, dystrophin expression in VSMCs appeared to influence the attenuation of NEmediated vasoconstriction that occurs in the contracting hindlimb, with the degree of attenuation being greatest in the wild type mice, least in the mdx mice, and intermediate in the SMTg/mdx mice.
Previous studies have attributed this contraction-induced attenuation to a paracrine effect of vasodilatory metabolites that are produced in the active muscle cells (32) . We therefore considered the possibility that dystrophin in VSMCs enhanced the dilator response to muscle-derived metabolites. However, we felt that this explanation was unlikely given the findings of our study and others that dystrophin deficiency in the mdx mouse does not appear to alter vascular reactivity per se to either constrictor (e.g., phenylephrine, KCl) or dilator (e.g., acetylcholine, nitroprusside)
stimuli (17, 31, 33) .
Instead, our results suggest that dystrophin in VSMCs facilitates an autocrine effect of NO to attenuate α-adrenergic constriction in the contracting mouse hindlimb. NOS inhibition prevented the contraction-induced attenuation of NE-mediated vasoconstriction in both the wild type and SMTg/mdx mice. The lack of an effect of NOS inhibition that we observed in the mdx mice was previously attributed to a deficiency of nNOS in skeletal muscle (16, 17) , which normally associates with the dystrophin complex at the sarcolemma but is secondarily reduced in the absence of dystrophin (23, 24). Whether nNOS associates with the dystrophin complex in VSMCs is not known, but we did find that nNOS protein was present in aortic tissue of wild type and SMTg/mdx mice, but not in that of mdx mice. Other investigators also have reported that nNOS is expressed in VSMCs, and have shown that NO generated in VSMCs can blunt constrictor responses, supporting an autocrine signaling role for NO in vascular tissue (29, 30, 34, 35) . Because dystrophin, nNOS, and α-adrenergic receptors have been localized to the cell membrane caveolae (36-38), we speculate that dystrophin deficiency may disrupt intrinsic signaling complexes that act in concert to regulate VSMC contractile activity.
Our novel finding that a reduced autocrine effect of NO in dystrophin-deficient VSMCs contributes to vascular dysregulation in the mdx mouse hindlimb complements previous studies showing impairments in paracrine signaling by NO in this same animal model (16, 17, 20, 33) . In addition to the effect of dystrophin deficiency in skeletal muscle cells to reduce sarcolemmal nNOS and attenuate the effect of muscle-derived NO to blunt α-adrenergic vasoconstriction, dystrophin deficiency in vascular endothelial cells has recently been implicated in an impaired NO-dependent dilator response to increased flow (shear stress) (16-18, 20, 33) . Collectively, the implications of these findings are that some dystrophin-deficient tissues, such as skeletal muscle, may have an increased susceptibility to develop ischemia. Whether the skeletal muscles of DMD patients or mdx mice are subject to varying degrees of functional ischemia during the course of normal daily activities is an important, but unanswered, question.
Another key unresolved question is whether aberrant vascular regulation contributes to the pathogenesis of the dystrophinopathies, for example, by inducing an ischemic stress that initiates or exacerbates injury of the dystrophin-deficient skeletal muscles. A remarkable pathological feature of the muscles of DMD patients and mdx mice that is observed early in the disease is the appearance of random groups of necrotic muscle fibers surrounded by histologically normal fibers (9, 10, 39, 40). Such grouped or focal necrosis can be reproduced in normal muscle by microvascular infarction, suggesting a causal role for ischemia (11) (12) (13) . This concept has been advanced in recent studies investigating the pathogenesis of cardiomyopathy characterized by focal necrosis in sarcoglycan-deficient mice, which are models of limb girdle muscular dystrophy (41) (42) (43) . In these mice, coronary vessel abnormalities resembling spasms precede the development of myocardial necrosis and elevation of cardiac-specific troponin I (41). Treatment with the calcium channel blocker verapamil ameliorated both the microvascular spasms and the cardiac muscle pathology, suggesting a pathogenetic role for vascular dysfunction (41, 43) .
In our study, serum CK levels were markedly reduced in 1-year old SMTg/mdx mice compared with values in the mdx mice, although they remained above values in the wild type mice.
Interestingly, the CK levels in the 3 genotypes corresponded with the degree of vascular dysregulation that we observed in the contracting hindlimbs of mice studied at 4 to 6 months of age.
Elevated CK levels are characteristic of increased membrane permeability (44) . For this reason, we also evaluated the uptake of Evans blue dye in muscle (45), but we observed no differences between SMTg/mdx and mdx mice at 6 to 7 months of age in these initial experiments (data not shown).
Clearly, further experiments are warranted to assess serial changes in CK levels and Evans blue dye uptake in these transgenic mice.
We also found that the proportion of muscle fibers with centralized nuclei did not differ in 1-year old mdx and SMTg/mdx mice, suggesting that muscle regeneration was not altered by dystrophin expression in smooth muscle. However, due to the characteristically high levels of muscle regeneration in the mdx mice, the majority of fibers already contain central nuclei by the age of 12 weeks (39, 40, 46). Other explanations for the lack of improvement in the histological phenotype of the SMTg/mdx mice might include the partial rather than complete normalization of vasoregulation in active muscle or the lower than normal level of dystrophin expression in VSMCs.
Because we did not study transgenic mice that were not crossed onto the mdx background, we do not know if the lower level of dystrophin expression in the SMTg/mdx mice was due to protein degradation on the mdx background. However, β-sarcoglycan and β-dystroglycan were detected by immunofluorescent staining in smooth muscle of SMTg/mdx mice, suggesting that this level of dystrophin was sufficient to restore the dystrophin-glycoprotein complex (41) . The SMTg/mdx mouse may provide a useful model to elucidate the effect of dystrophin in VSMCs on vascular structure as well as function. For example, arteriogenesis is enhanced in mdx mice in chronically ischemic hindlimb muscle and in wounded skin, but the tissue-specific role of dystrophin-deficiency in this neovascularization is unknown (47) . The SMTg/mdx mouse also could be used to determine if dystrophin expression in non-vascular smooth muscle ameliorates some of the gastrointestinal disorders or respiratory dysfunction that manifest in the dystrophinopathies.
In conclusion, we have shown that the expression of dystrophin in VSMCs of the dystrophin-deficient mdx mouse partially corrects the aberrant α-adrenergic vasoconstriction in exercising muscle and reduces serum CK, which is a classical index of active dystrophy. Dystrophin appears to be part of a local regulatory system in smooth muscle that uses NO as an autocrine modulator of α-adrenergic constriction. In the clinical setting of DMD, loss of this protective mechanism may leave the dystrophin-deficient skeletal muscle fibers vulnerable to ischemic insults, thereby exacerbating muscle fiber necrosis (48) . Our data suggest a potential benefit to restoring dystrophin in vascular smooth muscle in DMD.
MATERIALS AND METHODS
Transgene construct and production of transgenic mice
All animal experiments were approved by the committee of the Center for Animal Resources and Development, Kumamoto University.
Oligo-DNA including restriction enzyme, ApaI, SpeI, HindIII, NotI, SalI, EcoRI, and PstI site was synthesized, and subcloned into ApaI-PstI sites pBluescript II KS-(Stratagene, La Jolla, CA, USA) vectors, which removed NotI site by T4 DNApolymerase treatment, to generate BlueIIoligo. The HindIII-NotI fragment containing human smooth muscle α-actin promoter (EA 4.7 promoter) from pBS-HSMA-EA4.7, NotI-SalI fragment containing full-length human dystrophin (h-dys) cDNA, and EcoRI-XhoI fragment containing the SV-40 intron and poly-A signal from
BlNkacZ was inserted into BlueII-oligo in order to generate pEA 4.7-Dys-An (SMTg construct).
Finally, the SMTg construct, which expresses h-dys under control of EA 4.7 promoter, was generated in order to analyze dystrophin function in smooth muscle.
The construct, which was excised with SpeI, was microinjected into 800 fertilized oocyte pronuclei from C57BL/6 mice. They were returned to C57BL/6 recipients. The mice, which express dystrophin only in smooth muscle (SMTg/mdx), were produced by backcross of the transgenic mice with mdx mice. 
Reverse transcription-polymerase chain reaction (RT-PCR)
Semi quantitative real-time RT-PCR was performed using the ABI Prism 7900 Sequence Detector System® (PE Applied Biosystems). Total RNA was extracted from 9 tissues including brain, lung, aorta, heart, liver, kidney, skeletal muscle, small intestine and testis of one of SMTg/mdx lines Universal PCR Master Mix as described in the manufacturer's directions (PE Applied Biosystems).
The PCR was conducted using the following parameters: 50°C for 2 min, 95°C for 10 min and 40
cycles at 95°C for 15 s and 60°C for 1 min. Standard curve for the target amplicon was drawn using the transgene construction. All PCR assays were performed in duplicate and results are represented by the mean values. 18S rRNA was used as housekeeping gene against which all the samples were normalized for differences in the amount of total RNA added to each cDNA reaction and for variation in the reverse transcriptase efficiency among the different cDNA reactions.
Immunoblot analysis
Protein extracts of tibialis anterior muscle TA and aorta from three SMTg/mdx lines (n=2 per each line) at 1 year of age and age-matched control C57BL/10 (n=2) and mdx mice (n=2) were (1:10,000, Vector laboratories) or anti-rabbit antibody (1:10,000, VECTOR Laboratories). The antigen-antibody complex was magnified using the avidin-biotin complex (ABC) method, using the ABC kit (Vector Laboratories). Blots were developed using the ECL chemiluminescence system (Amersham).
Immunochemical staining for dystrophin and histological analysis
Immunohistochemistry during hindlimb contractions. These measurements were repeated in a subset of mice from each group after treatment with N-nitro-L-arginine methyl ester (L-NAME; 10 mg/kg, i.v.).
NE-mediated vasoconstriction was analyzed by measuring the change in femoral blood flow velocity or vascular conductance expressed as the maximal decrease from the pre-injection baseline (peak response) or as the integrated area below baseline (total response). Between group differences were evaluated using ANOVA followed by Tukey-Kramer post hoc tests. Within group differences (rest vs. contraction, before L-NAME vs. after L-NAME) were evaluated using paired t-tests (GraphPad Prism software, 4.0).
Serum creatine kinase level
The concentration of CK in serum collected by tail cutting was measured by a laboratory examination agency (SRL, Inc) as described by the manufacturer of the assay kit (Kanto Kagaku).
CK levels were determined in 1-year old C57BL/10, SMTg/mdx and mdx mice (n≥7 each).
Statistical significance of differences between groups was determined using Mann-Whitney test. The robust vasoconstrictor responses to NE that were observed in the resting hindlimbs of all 3 mice were attenuated in the contracting hindlimbs of the C57BL/10 mouse and to a lesser degree in the SMTg/mdx mouse, but not in the mdx mouse. 
